Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs can’t do? While a medicine that reverses the clock would be a ...

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

There are some potential downsides though, including misuse by those who do not need to lose weight, some gastric side-effects and in limited cases, potentially pancreatitis and gall bladder disorders ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

A new study of 60,000 people around the world is shedding light on the possible brain health benefits of popular weight-loss drugs like Ozempic and Wegovy, specifically for their potential to ...

Ozempic Might Be a Dementia Buster, Too Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia. By Ed Cara Published June 24, 2025 ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...